Cyxone (publ), a biotech company in autoimmune diseases, enters into a strategically important research collaboration with an acknowledged research group at University of Glasgow, UK, with the objective of performing an exploratory phase 2 study with rabeximod in patients with rheumatoid arthritis (RA).https://cyxone.com/en/
The research group at School of Infection and Immunity, University of Glasgow is an internationally recognised centre of excellence conducting high quality basic, translational and clinical research in the disciplines of infection, immunology and inflammation. The collaboration will be performed together with members of the Glasgow Rheumatic and Musculoskeletal Disease Group which is a world leading centre in RA research and other immune-mediated inflammatory diseases.
The researchers at the School of Infection and Immunity led by Professor Iain McInnes, also constitute one of the four corner stones of the consortium Research into Inflammatory Arthritis Centre Versus Arthritis (https://www.race-gbn.org/about/) (RACE), that together with the universities in Birmingham, Newcastle and Oxford have joined forces to perform translational research to gain a better understanding of the causes behind RA and how to treat it.
"We are excited to enter this research collaboration with the Cyxone team. It is a very interesting project that we see before us. And having followed the development of rabeximod over the years I am looking forward to now learn more about how the molecule works in greater detail", says Professor Iain McInnes, University of Glasgow.
"We are extremely pleased to be able to announce this strategically important collaboration around rabeximod. It is an honor that Cyxone now can establish this research collaboration with the University of Glasgow and their world-leading experts within RA research. With this, we will be able to learn much more about rabeximod and how the drug acts in the body by accessing the advanced state-of-the-art technologies that the scientists in Glasgow use in their research. The collaboration also provides access to the wider group of expertise that are in the British RA research consortium RACE, where a number of leading key opinion leaders take part, many of them already acquainted with Cyxone's project. We are really looking forward to this very important collaboration, and the learnings that will come out of it", says Carl-Magnus Högerkorp, CEO of Cyxone.
Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com